Arcus Biosciences Stock Analysis

RCUS Stock  USD 18.87  0.66  3.62%   
Arcus Biosciences is undervalued with Real Value of 24.02 and Target Price of 43.08. The main objective of Arcus Biosciences stock analysis is to determine its intrinsic value, which is an estimate of what Arcus Biosciences is worth, separate from its market price. There are two main types of Arcus Biosciences' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Arcus Biosciences' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Arcus Biosciences' stock to identify patterns and trends that may indicate its future price movements.
The Arcus Biosciences stock is traded in the USA on New York Stock Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Arcus Biosciences is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Arcus Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Arcus Biosciences' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcus Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment.
For more information on how to buy Arcus Stock please use our How to Invest in Arcus Biosciences guide.

Arcus Stock Analysis Notes

About 41.0% of the company outstanding shares are owned by corporate insiders. The book value of Arcus Biosciences was at this time reported as 6.12. The company recorded a loss per share of 4.15. Arcus Biosciences had not issued any dividends in recent years. Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company was incorporated in 2015 and is headquartered in Hayward, California. Arcus Biosciences operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 366 people. To find out more about Arcus Biosciences contact Terry Rosen at 510 694 6200 or learn more at https://www.arcusbio.com.

Arcus Biosciences Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Arcus Biosciences' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Arcus Biosciences or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Arcus Biosciences had very high historical volatility over the last 90 days
The company reported the previous year's revenue of 117 M. Net Loss for the year was (307 M) with loss before overhead, payroll, taxes, and interest of (176 M).
Arcus Biosciences currently holds about 1.05 B in cash with (306 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.48.
Arcus Biosciences has a poor financial position based on the latest SEC disclosures
Roughly 60.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: Arcus Biosciences Shares Up 7.6 percent - MarketBeat

Arcus Biosciences Upcoming and Recent Events

Earnings reports are used by Arcus Biosciences to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Arcus Biosciences previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
27th of February 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Arcus Largest EPS Surprises

Earnings surprises can significantly impact Arcus Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2020-11-05
2020-09-300.050.03-0.0240 
2019-05-02
2019-03-31-0.35-0.41-0.0617 
2020-05-05
2020-03-31-0.56-0.63-0.0712 
View All Earnings Estimates

Arcus Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Arcus Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Arcus Biosciences backward and forwards among themselves. Arcus Biosciences' institutional investor refers to the entity that pools money to purchase Arcus Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Goldman Sachs Group Inc2023-12-31
1.2 M
Geode Capital Management, Llc2023-12-31
1.1 M
Woodline Partners Lp2023-12-31
M
Suvretta Capital Management, Llc2023-12-31
957.3 K
Decheng Capital Llc2023-12-31
869.8 K
Morgan Stanley - Brokerage Accounts2023-12-31
701.4 K
Bnp Paribas Investment Partners Sa2023-12-31
539.7 K
Northern Trust Corp2023-12-31
524.7 K
Balyasny Asset Management Llc2023-12-31
515.5 K
Blackrock Inc2023-12-31
10 M
Fmr Inc2023-12-31
4.7 M
Note, although Arcus Biosciences' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Arcus Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.51 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Arcus Biosciences's market, we take the total number of its shares issued and multiply it by Arcus Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Arcus Profitablity

Arcus Biosciences' profitability indicators refer to fundamental financial ratios that showcase Arcus Biosciences' ability to generate income relative to its revenue or operating costs. If, let's say, Arcus Biosciences is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Arcus Biosciences' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Arcus Biosciences' profitability requires more research than a typical breakdown of Arcus Biosciences' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (2.62) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.94) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.94.
Last ReportedProjected for 2024
Return On Capital Employed(0.37)(0.39)
Return On Assets(0.28)(0.29)
Return On Equity(0.66)(0.70)

Management Efficiency

Arcus Biosciences has return on total asset (ROA) of (0.1742) % which means that it has lost $0.1742 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5487) %, meaning that it created substantial loss on money invested by shareholders. Arcus Biosciences' management efficiency ratios could be used to measure how well Arcus Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to drop to -0.39 in 2024. Return On Assets is likely to drop to -0.29 in 2024. At this time, Arcus Biosciences' Net Tangible Assets are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 113 M in 2024, whereas Total Assets are likely to drop slightly above 767.6 M in 2024.
Last ReportedProjected for 2024
Price Book Value Ratio 3.06  3.36 
Enterprise Value Multiple(4.46)(4.24)
Price Fair Value 3.06  3.36 
The analysis of Arcus Biosciences' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Arcus Biosciences' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Arcus Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta
0.812

Technical Drivers

As of the 28th of March, Arcus Biosciences shows the risk adjusted performance of 0.0276, and Mean Deviation of 3.06. In respect to fundamental indicators, the technical analysis model gives you tools to check existing technical drivers of Arcus Biosciences, as well as the relationship between them. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We are able to break down and analyze data for nineteen technical drivers for Arcus Biosciences, which can be compared to its rivals. Please confirm Arcus Biosciences mean deviation, information ratio, as well as the relationship between the Information Ratio and downside variance to decide if Arcus Biosciences is priced correctly, providing market reflects its regular price of 18.87 per share. Given that Arcus Biosciences has jensen alpha of (0.24), we suggest you to validate Arcus Biosciences's prevailing market performance to make sure the company can sustain itself at a future point.

Arcus Biosciences Price Movement Analysis

The output start index for this execution was two with a total number of output elements of fifty-nine. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Arcus Biosciences middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Arcus Biosciences. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Arcus Biosciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arcus Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arcus Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Arcus Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Arcus Biosciences Predictive Daily Indicators

Arcus Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Arcus Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Arcus Biosciences Corporate Filings

F4
20th of March 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
28th of February 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
23rd of February 2024
Other Reports
ViewVerify
8K
21st of February 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
13A
13th of February 2024
An amended filing to the original Schedule 13G
ViewVerify
13A
9th of February 2024
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
F3
7th of February 2024
The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock
ViewVerify
F3
31st of January 2024
An amendment to the original Schedule 13D filing
ViewVerify

Arcus Biosciences Forecast Models

Arcus Biosciences' time-series forecasting models are one of many Arcus Biosciences' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Arcus Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Arcus Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Arcus Biosciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Arcus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Arcus Biosciences. By using and applying Arcus Stock analysis, traders can create a robust methodology for identifying Arcus entry and exit points for their positions.
Last ReportedProjected for 2024
Pretax Profit Margin(2.57)(2.70)
Operating Profit Margin(2.91)(3.05)
Net Loss(2.62)(2.76)
Gross Profit Margin 0.86  0.91 

Current Arcus Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Arcus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Arcus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
43.08Strong Buy11Odds
Arcus Biosciences current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Arcus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Arcus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Arcus Biosciences, talking to its executives and customers, or listening to Arcus conference calls.
Arcus Analyst Advice Details

Arcus Stock Analysis Indicators

Arcus Biosciences stock analysis indicators help investors evaluate how Arcus Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Arcus Biosciences shares will generate the highest return on investment. By understating and applying Arcus Biosciences stock analysis, traders can identify Arcus Biosciences position entry and exit signals to maximize returns.
Begin Period Cash Flow209 M
Common Stock Shares Outstanding74 M
Total Stockholder Equity462 M
Tax ProvisionM
Property Plant And Equipment Net51 M
Cash And Short Term Investments759 M
Cash127 M
Accounts Payable17 M
Net Debt-116 M
50 Day M A17.027
Total Current Liabilities184 M
Other Operating Expenses457 M
Non Current Assets Total264 M
Non Currrent Assets Other106 M
Stock Based Compensation73 M
When determining whether Arcus Biosciences is a strong investment it is important to analyze Arcus Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Arcus Biosciences' future performance. For an informed investment choice regarding Arcus Stock, refer to the following important reports:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcus Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment.
For more information on how to buy Arcus Stock please use our How to Invest in Arcus Biosciences guide.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for Arcus Stock analysis

When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Is Arcus Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcus Biosciences. If investors know Arcus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcus Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.15)
Revenue Per Share
1.581
Quarterly Revenue Growth
(0.09)
Return On Assets
(0.17)
Return On Equity
(0.55)
The market value of Arcus Biosciences is measured differently than its book value, which is the value of Arcus that is recorded on the company's balance sheet. Investors also form their own opinion of Arcus Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Arcus Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcus Biosciences' market value can be influenced by many factors that don't directly affect Arcus Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcus Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcus Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcus Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.